

RECORDATION FORM COVER SHEET

TRADEMARKS ONLY

Our Ref.: 4379-11

Mail Stop Assignment Recordation Services

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

To the Commissioner for Trademarks: Please record the attached original documents or copy thereof.

<p>1. Name of conveying party(ies): <b>VERUS PHARMACEUTICALS, INC.</b></p> <p><input type="checkbox"/> Individual(s)                      <input type="checkbox"/> Association  <input type="checkbox"/> General partnership              <input type="checkbox"/> Limited Partnership  <input checked="" type="checkbox"/> Corporation-State:      Delaware  <input type="checkbox"/> Other:</p>	<p>2. Name and address of receiving party(ies): Name(s): <b>PAUL ROYALTY FUND HOLDINGS II</b> Address:      50 California Street                  Suite 3000 City: San Francisco State/Country: California Zip: 94111</p> <p><input type="checkbox"/> Individual(s) citizenship  <input type="checkbox"/> Association  <input type="checkbox"/> General Partnership</p> <p><input checked="" type="checkbox"/> Limited Partnership  <input type="checkbox"/> Corporation-State  <input type="checkbox"/> Other</p> <p>If assignee is not domiciled in the United States, a domestic representative designation is attached:      <input type="checkbox"/> Yes      <input checked="" type="checkbox"/> No</p>
<p>3. Nature of conveyance: <input checked="" type="checkbox"/> <b>OTHER: Grant of a Security Interest in Grantor's (Debtor's) Licensed Rights to Grantee (Secured Party)</b></p> <p>Execution Date:                                      April 1, 2005</p>	<p>Designations must be a separate document from Assignment) Additional name/s &amp; address/es attached      <input type="checkbox"/> Yes      <input checked="" type="checkbox"/> No</p>

4. Application number(s) or registration number(s):

If this document is being filed together with a new application, the execution date of the application is:


<p>A. Trademark Application No.(s) (1) <b>76/309,722</b> (2) <b>78/470,999</b></p>	<p>B. Trademark Registration No.(s) (1) _____ (2) _____</p>
--	---

Additional numbers attached?       Yes       No

<p>5. Name and address of party to whom correspondence concerning document should be mailed: Name: <b>Willem F. Gadiano</b></p> <p>Street Address      Nixon &amp; Vanderhye P.C.                                  901 North Glebe Road                                  11th Floor City      Arlington      State:      VA      Zip:      22203</p>	<p>6. Total number of applications and registrations involved:      <u>2</u></p> <p>7. Total fee (37 CFR 3.41)    \$      <u>65</u></p> <p><input type="checkbox"/> Enclosed  <input checked="" type="checkbox"/> Authorized to be charged to deposit account #14-1140</p> <p>8. The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper thereafter filed in this application by this firm) to our <b>Account No. 14-1140.</b></p>
--	---

**DO NOT USE THIS SPACE**

9. Statements and signature.  
To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.


<p><u>Willem F. Gadiano</u> Name of Person Signing</p>	<p> Signature</p>	<p><u>August 26, 2005</u> Date</p>
--	---	--

Total number of pages including cover sheet, attachments and document:      8


**CERTIFICATE OF FACSIMILE TRANSMISSION**

I hereby certify that this document (including any paper referred to as being attached or enclosed) is being sent to the U.S. Patent and Trademark Office via facsimile transmission to (571) 273-0140 on the date indicated below, with a coversheet addressed to Commissioner for Patents, U.S. Patent and Trademark Office.

Date: August 26, 2005

By:   
Willem F. Gadiano, Reg. No. 37,136

CH \$65.00 141140 76309722



DELAWARE DEPARTMENT OF STATE  
U.C.C. FILING SECTION  
FILED 02:20 PM 04/01/2005  
INITIAL FILING NUM: 5100710 4  
AMENDMENT NUMBER: 000000  
SRV: 050266725

**UCC FINANCING STATEMENT**

FOLLOW INSTRUCTIONS (front and back) CAREFULLY

A. NAME & PHONE OF CONTACT AT FILER (optional)

B. SEND ACKNOWLEDGMENT TO: (Name and Address)

Sharmila Achari  
Morgan, Lewis & Bockius LLP  
101 Park Avenue  
New York, NY 10178

THE ABOVE SPACE IS FOR FILING OFFICE USE ONLY

**1 DEBTOR'S EXACT FULL LEGAL NAME** - Insert only name of debtor (T or F) - do not abbreviate or combine names

1a. ORGANIZATION'S NAME  
Veras Pharmaceuticals, Inc.

OR 1b. INDIVIDUAL'S LAST NAME FIRST NAME MIDDLE NAME SUFFIX

1c. MAILING ADDRESS CITY STATE POSTAL CODE COUNTRY  
12671 High Bluff Drive, Suite 200 San Diego CA 92130 USA

1d. ASSIGNMENT ADDL INFO RE ORG TYPE OF ORGANIZATION 1e. JURISDICTION OF ORGANIZATION 1f. ORGANIZATIONAL ID# (if any)  
DEBTOR CORPORATION Delaware NONE

**2 ADDITIONAL DEBTOR'S EXACT FULL LEGAL NAME** - Insert only one debtor name (a or b) - do not abbreviate or combine names

2a. ORGANIZATION'S NAME

OR 2b. INDIVIDUAL'S LAST NAME FIRST NAME MIDDLE NAME SUFFIX

2c. MAILING ADDRESS CITY STATE POSTAL CODE COUNTRY

2d. ASSIGNMENT ADDL INFO RE ORG TYPE OF ORGANIZATION 2e. JURISDICTION OF ORGANIZATION 2f. ORGANIZATIONAL ID# (if any)  
DEBTOR NONE

**3 SECURED PARTY'S NAME** (or NAME of TOTAL ASSIGNOR of ASSIGNOR (SP) - insert only one secured party name (a or b))

3a. ORGANIZATION'S NAME  
Paul Royalty Funds Holdings II

OR 3b. INDIVIDUAL'S LAST NAME FIRST NAME MIDDLE NAME SUFFIX

3c. MAILING ADDRESS CITY STATE POSTAL CODE COUNTRY  
50 California Street, Suite 3000 San Francisco CA 94111 USA

**4 This FINANCING STATEMENT covers the following collateral:**

All of the Debtor's right, title and interest in the Collateral Intellectual Property, the Collateral Product, the Collateral License Agreement, and all other rights to the items contained within the collateral description, as more fully set forth on Schedule I attached hereto.

5. ALTERNATIVE DESIGNATION (if applicable) 6. FILING OFFICE (if different from that of the debtor) 7. Check to PREPARE SEARCH REPORT(s) on DEBTOR'S ADDITIONAL FEES 8. OPTIONAL FILER REFERENCE DATA

DE-SOS

TRADEMARK

227870ML

209

**SCHEDULE 1 TO UCC-1 FINANCING STATEMENT**

**Debtor:** Verus Pharmaceuticals, Inc.  
12671 High Bluff Drive  
Suite 200  
San Diego, CA 92130

**Secured Party:** Paul Royalty Funds Holdings II  
50 California Street  
Suite 3000  
San Francisco, CA 94111

**DEFINITIONS:**

"Collateral Intellectual Property" shall mean trade secrets; know-how; confidential information; inventions (whether patentable or unpatentable and whether or not reduced to practice or claimed in a pending patent application) and improvements thereto; patents; registered or unregistered trademarks, trade names, service marks, including all goodwill associated therewith; registered and unregistered copyrights and all applications thereof; in each case that are owned, controlled by, issued to, licensed to, licensed by or hereafter acquired by or licensed by the Debtor, in each case embodied by, encompassing or necessary for the Collateral Product

"Collateral License Agreements" shall mean any development, commercialization, distribution, co-promotion, manufacturing, marketing, co-marketing, collaboration or partnering agreement entered into by Debtor or any of its affiliates as of March 29, 2005 or during the term of the Revenue Interests Assignment Agreement entered into as of March 29, 2005, between the Debtor and the Secured Party (the "Revenue Interests Assignment Agreement") pursuant to which the Debtor or its affiliates grant rights or licenses relating to any Collateral Product that has received regulatory approval in a regulatory jurisdiction as of the date of inquiry.

"Collateral Product" shall mean any product that has received regulatory approval in a regulatory jurisdiction for anaphylaxis, anaphylactic shock and/or the emergency treatment of severe allergic reactions relating to anaphylaxis, including without limitation the products currently referred to as Twinject 0.3 mg, Twinject 0.15 mg, Twinject 0.3 mg 2-Pack and Twinject 0.15 mg 2-Pack.

All capitalized terms used herein and not defined above are defined within the Security Agreement, dated as of March 29, 2005, between the Debtor and Verus.

**COLLATERAL:**

All of the Debtor's right, title, and interest in the in the following personal property, whether now or hereafter existing, whether tangible or intangible, and wherever the same may be located:

**TRADEMARK****REEL: 003180 FRAME: 0429**

- (a) the Collateral Intellectual Property and the Collateral Product;
- (b) the Collateral License Agreements, including, without limitation, (i) all rights of Debtor to receive monies due or to become due under or pursuant to the Collateral License Agreements, (ii) all rights of Debtor to receive proceeds of any insurance, indemnity, warranty or guaranty with respect to the Collateral License Agreements, (iii) all claims of Debtor for damages arising out of any breach of or default under the Collateral License Agreements, and (iv) all rights of Debtor to terminate, amend, supplement, modify or exercise rights or options under the Collateral License Agreements, except as otherwise set forth in the Revenue Interests Assignment Agreement, to perform thereunder and to compel performance and otherwise exercise all remedies thereunder;
- (c) all Accounts, contract rights, payment intangibles, Instruments and General Intangibles, in each case, constituting, comprising or evidencing any of the foregoing;
- (d) certain identified Deposit Accounts and all funds, monies, Checks and other items from time to time credited thereto or on deposit therein;
- (e) all books, records, databases, information, clinical data, test results, study results and regulatory filings and approvals, in each case, specifically relating to any of the foregoing;
- (f) all proceeds, products, rents and profits, of or from, and all tangible property and inventories related to, any and all of the foregoing, the Assigned Interests, the Revenue Interests, and, to the extent not otherwise included, all payments under insurance (whether or not Secured Party is the loss payee thereof), or any indemnity, warranty or guaranty, payable by reason of loss or damage to or otherwise with respect to any of the foregoing; and
- (g) all rights to license or otherwise exploit the Collateral Intellectual Property

Notwithstanding the foregoing, "Collateral" shall not include any lease, license, or contract if and for so long as the grant of such security interest shall constitute or result in (i) the abandonment, invalidation or unenforceability of any right, title or interest of Debtor therein or (ii) a breach or termination pursuant to the terms of, or a default under, any such lease, license, contract or agreement (other than to the extent that any such term would be rendered ineffective pursuant to Sections 9-406, 9-407, 9-408 or 9-409 of the UCC).

**Twinject Intellectual Property****PATENTS/PATENT APPLICATIONS (LICENSED BY H-S FROM WASHINGTON BIOTECH)**

U.S. 5,540,664

U.S. 5,358,489

U.S. 5,833,669

U.S. 5,665,071

U.S. APPLICATION NO. 11/006,382 (FILED DECEMBER 6, 2004)

AND ALL CORRESPONDING FOREIGN PATENTS AND APPLICATIONS TO THE ABOVE, AND ANY RELATED APPLICATIONS TO THE PENDING US APPLICATION.

U.S. TRADEMARK REGISTRATIONS AND APPLICATIONS

MARK	SER./ REG. #	FILING/ REG. DATE
TWINJECTJR	SER# 78124892	FILED 04/29/2002
TWINDOSEJR	SER# 78124887	FILED 04/29/2002
TWINDOSE	SER# 78124884	FILED 04/29/2002
DUODOSE	SER# 78124880	FILED 04/29/2002
DUODOSEJR	SER# 78124882	FILED 04/29/2002
TWINDOSE	SER# 75508746 (abandoned)	FILED 06/25/1998
TWINDOSEJR	SER# 75508742 (abandoned)	FILED 06/25/1998
TWINJECT	SER# 75350162 (abandoned)	FILED 09/02/1997
TWINJECT	SER# 78470999	FILED 08/20/2004
TWINJECT	SER# 76309722	FILED 09/06/2001
TWINJECT PD	SER# 76311697	FILED 09/12/2001
TWINJECT PED	SER# 76311698	FILED 09/12/2001
TWINJECT JR	SER# 75442068 (abandoned)	FILED 02/27/1998
ANATWINJR	SER# 75508744 (abandoned)	FILED 06/25/1998
ANATWIN	SER# 75508740 (abandoned)	FILED 06/25/1998
BIPHINE JR.	SER# 75327518 (abandoned)	FILED 07/21/1997
BIPHINE	SER# 75327517 (abandoned)	FILED 07/21/1997
DUODOSE	SER# 75508747 (abandoned)	FILED 06/25/1998
DUODOSE JR	SER# 75508741 (abandoned)	FILED 06/25/1998
ANAKIT	REG# 1564139	REG. DATE 11/07/1989
ANA-GUARD	REG# 1643320	REG. DATE 05/07/1991
ANA-KIT (and design)	REG# 1939510	REG. DATE 12/05/1995
ANA-KIT	REG# 1961512	REG. DATE 03/12/1996

FOREIGN TRADEMARK REGISTRATIONS AND APPLICATIONS

COUNTRY	MARK	APP./ REG. #	FILING/ REG. DATE
CANADA	ANAKIT DESIGN	REG.# TMA225641	REG. DATE 01/27/1978
CANADA	TWINJECT	APP.# 1154855	FILED 10/04/2002
CANADA	TWINJECT PD	APP.# 1154856	FILED 10/04/2002
COMMUNITY TRADEMARKS	TWINJECT PD	APP.# 2603082 REG # 2603082	FILED 03/05/2002 REG. DATE 07/10/2003
COMMUNITY TRADEMARKS	TWINJECT	APP.# 2542173	FILED 01/21/2002

DOMAIN NAMES

TWINJECT.COM

TWINJECT.BIZ

TWINJECT.INFO

TWINJECT.NET

TWINJECT.ORG